HUE029510T4 - Prokaryotic phenylalanine ammonia-lyase compositions, and a method for treating cancer with derived products - Google Patents

Prokaryotic phenylalanine ammonia-lyase compositions, and a method for treating cancer with derived products Download PDF

Info

Publication number
HUE029510T4
HUE029510T4 HUE08795357A HUE08795357A HUE029510T4 HU E029510 T4 HUE029510 T4 HU E029510T4 HU E08795357 A HUE08795357 A HU E08795357A HU E08795357 A HUE08795357 A HU E08795357A HU E029510 T4 HUE029510 T4 HU E029510T4
Authority
HU
Hungary
Prior art keywords
avpal
leu
ala
gly
ser
Prior art date
Application number
HUE08795357A
Other languages
English (en)
Hungarian (hu)
Inventor
Michel C Vellard
Paul A Fitzpatrick
Emil D Kakkis
Daniel J Wendt
Mubarack Muthalif
Sean M Bell
Augustus O Okhamafe
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40363135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE029510(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of HUE029510T2 publication Critical patent/HUE029510T2/hu
Publication of HUE029510T4 publication Critical patent/HUE029510T4/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE08795357A 2007-08-17 2008-08-15 Prokaryotic phenylalanine ammonia-lyase compositions, and a method for treating cancer with derived products HUE029510T4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6612507P 2007-08-17 2007-08-17

Publications (2)

Publication Number Publication Date
HUE029510T2 HUE029510T2 (hu) 2017-02-28
HUE029510T4 true HUE029510T4 (en) 2017-05-29

Family

ID=40363135

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08795357A HUE029510T4 (en) 2007-08-17 2008-08-15 Prokaryotic phenylalanine ammonia-lyase compositions, and a method for treating cancer with derived products

Country Status (23)

Country Link
US (4) US7560263B2 (https=)
EP (1) EP2175875B1 (https=)
JP (1) JP5584120B2 (https=)
CN (1) CN101803492B (https=)
AR (2) AR067972A1 (https=)
AU (1) AU2008289549B2 (https=)
BR (2) BR122018072594B8 (https=)
CA (1) CA2687028C (https=)
CL (1) CL2008002390A1 (https=)
CY (1) CY1118222T1 (https=)
DK (1) DK2175875T3 (https=)
ES (1) ES2602618T3 (https=)
HR (1) HRP20161474T1 (https=)
HU (1) HUE029510T4 (https=)
LT (1) LT2175875T (https=)
MX (1) MX2009012261A (https=)
PE (1) PE20090605A1 (https=)
PL (1) PL2175875T3 (https=)
PT (1) PT2175875T (https=)
RU (2) RU2553343C2 (https=)
SI (1) SI2175875T1 (https=)
TW (1) TWI418787B (https=)
WO (1) WO2009025760A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
WO2010014225A2 (en) * 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2011078667A2 (en) 2009-12-22 2011-06-30 Dsm Ip Assets B.V. Method of finding a biocatalyst having ammonia lyase activity
ES2690542T3 (es) 2010-02-04 2018-11-21 Biomarin Pharmaceutical Inc. Método para purificar variantes de fenilalanina amoníaco-liasa procariotas
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
AU2013295621A1 (en) * 2012-07-27 2015-03-12 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (PKU) disease
NZ713396A (en) 2013-04-18 2020-06-26 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
CA2930665A1 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
MA39819A (fr) 2014-04-01 2017-02-08 Rubius Therapeutics Inc Méthodes et compositions d'immunomodulation
WO2015161019A1 (en) 2014-04-16 2015-10-22 Codexis, Inc. Engineered tyrosine ammonia lyase
CN106456723B (zh) 2014-04-29 2021-03-09 康达医药科技有限公司 采用精氨酸酶i调节免疫系统的方法和组合物
US10752923B2 (en) 2014-07-14 2020-08-25 Cysbio Aps Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity
LT3237621T (lt) 2014-12-22 2023-09-25 Codexis, Inc. Žmogaus alfa-galaktozidazės variantai
IL305149A (en) 2016-07-26 2023-10-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
IT201600086488A1 (it) * 2016-08-22 2018-02-22 St Microelectronics Srl Dispositivo a semiconduttore e corrispondente procedimento
MX2019009615A (es) 2017-02-13 2019-10-14 Codexis Inc Polipeptidos dise?ados de fenilalanina amonio liasa.
TW202016314A (zh) 2018-05-09 2020-05-01 美商拜奧馬林製藥公司 治療苯丙酮尿症之方法
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US10900055B2 (en) 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
CA3122524A1 (en) 2018-12-14 2020-06-18 Codexis, Inc. Engineered tyrosine ammonia lyase
AU2019403323B2 (en) 2018-12-20 2026-02-26 Codexis, Inc. Human alpha-galactosidase variants
EP3923988B1 (en) 2019-02-14 2025-04-30 Som Innovation Biotech, S.A. Triamterene or nolatrexed for use in the treatment of phenylketonuria
CN114585391A (zh) * 2019-08-07 2022-06-03 乐天医药生技股份有限公司 西妥昔单抗-ir700偶联物组合物
EP4501403A3 (en) 2019-08-30 2025-05-14 Société des Produits Nestlé S.A. Engineered lipase variants
JP2023507575A (ja) 2019-12-20 2023-02-24 コデクシス, インコーポレイテッド 操作された酸性アルファ-グルコシダーゼバリアント
JP2023512683A (ja) 2020-02-04 2023-03-28 コデクシス, インコーポレイテッド 操作されたロイシンデカルボキシラーゼ
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用aav及治療調配物之苯酮尿症治療
CN116897205A (zh) 2020-08-28 2023-10-17 科德克希思公司 工程化淀粉酶变体
AU2021334371A1 (en) 2020-08-28 2023-03-09 Codexis, Inc. Engineered protease variants
EP4341394A4 (en) 2021-05-19 2025-04-09 BioMarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia lyase and methods for treating adolescent patients
CA3220735A1 (en) 2021-05-21 2022-11-24 Codexis, Inc. Engineered methionine gamma lyase variants
JP2024540358A (ja) 2021-11-01 2024-10-31 シンティス バイオ,インコーポレイティド 工学操作ロイシン脱炭酸酵素
CN115873837A (zh) * 2022-11-18 2023-03-31 安徽盈科生物科技有限公司 高表达的新型的苯丙氨酸解氨酶
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
US20250161466A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5212939A (en) * 1991-12-04 1993-05-25 Pratt Jr John M Marine mooring swivel fitting
JP2930723B2 (ja) 1992-11-19 1999-08-03 アンティキャンサー インコーポレーテド 抗メチオニン化学療法における抗腫瘍薬としてのメチオニナーゼの使用
EP0692029B1 (en) 1992-12-04 2007-05-09 Me Medical Enzymes Ag Genetically engineered glutaminase and its use in therapy
DK75593D0 (https=) 1993-06-25 1993-06-25 Novo Nordisk As
KR0164757B1 (ko) * 1995-06-13 1999-01-15 김광호 공조장치의 살균집진장치와 그 방법
DK0851925T3 (da) 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
CU22585A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
US6395299B1 (en) 1999-02-12 2002-05-28 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001257032A1 (en) 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
US6939941B2 (en) * 2001-09-12 2005-09-06 Toray Fine Chemicals Co., Ltd. Preparation of polysulfide compositions
KR20040088538A (ko) 2002-02-26 2004-10-16 이 아이 듀폰 디 네모아 앤드 캄파니 유전 인자의 재조합 방법
JP2006516095A (ja) 2002-11-14 2006-06-22 ザ スクリップス リサーチ インスティテュート 脂肪酸アミドヒドロラーゼ(faah)の結晶形
WO2006034373A2 (en) 2004-09-17 2006-03-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP2886658A1 (en) * 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
DE102006032167B4 (de) 2006-07-12 2014-11-27 Evonik Degussa Gmbh Verfahren zur Herstellung von Triallylisocyanurat (TAIC)
US20090011400A1 (en) 2006-12-01 2009-01-08 The Salk Institute for Biological Studies and The Regents of the University of California Substrate switched ammonia lyases and mutases
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase

Also Published As

Publication number Publication date
PL2175875T3 (pl) 2017-04-28
US7790433B2 (en) 2010-09-07
SI2175875T1 (sl) 2017-01-31
US7537923B2 (en) 2009-05-26
PT2175875T (pt) 2016-11-21
ES2602618T3 (es) 2017-02-21
HUE029510T2 (hu) 2017-02-28
CA2687028C (en) 2016-02-16
JP2010536759A (ja) 2010-12-02
AR117389A2 (es) 2021-08-04
TW200911283A (en) 2009-03-16
BR122018072594B1 (pt) 2020-10-27
RU2553343C2 (ru) 2015-06-10
WO2009025760A3 (en) 2009-06-25
CN101803492B (zh) 2014-05-07
EP2175875B1 (en) 2016-10-05
BRPI0811589B8 (pt) 2021-05-25
CN101803492A (zh) 2010-08-11
BR122018072594B8 (pt) 2021-07-27
AU2008289549B2 (en) 2014-02-06
CY1118222T1 (el) 2017-06-28
US20090263369A1 (en) 2009-10-22
BRPI0811589B1 (pt) 2020-05-12
PE20090605A1 (es) 2009-05-16
HRP20161474T1 (hr) 2016-12-30
BRPI0811589A2 (pt) 2014-10-29
US7560263B2 (en) 2009-07-14
RU2009141987A (ru) 2011-05-20
AR067972A1 (es) 2009-10-28
AU2008289549A1 (en) 2009-02-26
US20100278802A1 (en) 2010-11-04
DK2175875T3 (en) 2016-11-21
WO2009025760A2 (en) 2009-02-26
TWI418787B (zh) 2013-12-11
EP2175875A2 (en) 2010-04-21
CL2008002390A1 (es) 2009-05-29
RU2012134838A (ru) 2014-03-20
JP5584120B2 (ja) 2014-09-03
MX2009012261A (es) 2010-03-15
US20090047265A1 (en) 2009-02-19
CA2687028A1 (en) 2009-02-26
LT2175875T (lt) 2016-12-12
US20090047268A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
DK2175875T3 (en) COMPOSITIONS OF PROCARYOTIC PHENYLALANINE AMMONIAK LYASE AND METHODS FOR TREATING CANCER USING ITS COMPOSITIONS THEREOF
US20240035013A1 (en) Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof
KR101603796B1 (ko) 원핵생물 페닐알라닌 암모니아-리아제의 조성물, 및 상기 조성물의 사용 방법
HK1225299A1 (en) Method for purifying prokaryotic phenylalanine ammonia-lyase variants
HK1136499B (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
HK40081555A (en) Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
HK40008404A (en) Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
HK1135141B (en) Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using said compositions